← All candidates
One insider buy in the last year — $3.00M in all.
23 filings on record.
IKTInhibikase Therapeutics, Inc.
NasdaqCM · Healthcare · $326.51M
$2.34
+0.43% · Sep 11
One insider buy in the last year — $3.00M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy◆ 4 8-K
▸ hover a marker for the filing · drag to zoom · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$326.51M
Float
107.1M
77% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Sands Capital Life Sciences Pulse Fund II, L.P.
Bought $3.00M on Nov 21 — 2,068,965 sh @ $1.45, held direct, 16% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
3 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
2 more transactions on Pro →The file stays open
23 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice